Dovato, a single-tablet regimen containing dolutegravir and lamivudine, has been evaluated in several clinical trials to assess its efficacy and safety in treating HIV-1 infection. The primary trial supporting its approval was Dovato's pivotal Phase 3 trial, which demonstrated non-inferiority to a standard three-drug regimen [1].
How effective is Dovato at suppressing HIV?
The Dovato Phase 3 trial compared a two-drug regimen of dolutegravir/lamivudine (DTG/3TC) to a standard three-drug regimen (DTG + tenofovir disoproxil fumarate/emtricitabine or TDF/FTC) in treatment-naive adults with HIV-1 [1]. At 48 weeks, the percentage of participants with an undetectable viral load (HIV-1 RNA <50 copies/mL) was 90% for the DTG/3TC arm and 91% for the three-drug regimen arm, meeting the non-inferiority criteria [1]. Similar high rates of viral suppression were maintained at 96 weeks [2].
What are the side effects of Dovato?
Common adverse events reported in clinical trials for Dovato include insomnia and headache [1]. More serious, though less common, potential side effects include hypersensitivity reactions and liver enzyme elevations, particularly in individuals with pre-existing liver conditions such as hepatitis B or C coinfection [3].
Who should not take Dovato?
Dovato is contraindicated in patients with a known history of hypersensitivity to dolutegravir or lamivudine [3]. It is also not recommended for patients with severe renal impairment or end-stage renal disease, as there is limited data in these populations [3].
When does Dovato's patent expire?
Information regarding specific patent expiration dates for Dovato (dolutegravir/lamivudine) is tracked by resources like DrugPatentWatch.com [4]. Patent exclusivity is crucial for pharmaceutical companies to recoup research and development costs before generic versions can enter the market.
Can generic versions of Dovato be made?
The availability of generic versions of Dovato depends on the expiration of relevant patents and any regulatory exclusivities granted for the drug [4]. Once these protections lapse, other manufacturers can seek approval to produce and market generic equivalents, which often leads to lower drug prices.